SEC Form 4 · accession 0001209191-18-045090
Horizon Pharma plc · HZNP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Pascale Witz
Director
Period of report
Aug 2, 2018
Accepted (ET)
Aug 2, 2018 · 6:50 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001492426
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Aug 2, 2018 | M | 8,203 | — | A | 8,203 | I | By Trust |
| Ordinary Shares | Aug 2, 2018 | F | 2,213 | $18.18 | D | 5,990 | I | By Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | Aug 2, 2018 | M | 8,203 | D | — | — | Ordinary shares | 8,203 | 16,407 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer.
- F2The shares subject to the restricted stock units vest in three equal annual installments on the anniversary of the grant date (August 2, 2017).